Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)2D, but No Difference in Ratio of 25(OH)D/24,25(OH)2D and FGF23 Concentrations. 2019

Mariska C Vlot, and Laura Boekel, and Jolijn Kragt, and Joep Killestein, and Barbara M van Amerongen, and Robert de Jonge, and Martin den Heijer, and Annemieke C Heijboer
Department of Clinical Chemistry, Endocrine Laboratory, Amsterdam University Medical Center, 1081 HV Amsterdam, The Netherlands.

Vitamin D (VitD) insufficiency is common in multiple sclerosis (MS). VitD has possible anti-inflammatory effects on the immune system. The ratio between VitD metabolites in MS patients and the severity of the disease are suggested to be related. However, the exact effect of the bone-derived hormone fibroblast-growth-factor-23 (FGF23) and VitD binding protein (VDBP) on this ratio is not fully elucidated yet. Therefore, the aim is to study differences in total, free, and bioavailable VD metabolites and FGF23 between MS patients and healthy controls (HCs). FGF23, vitD (25(OH)D), active vitD (1,25(OH)2D), inactive 24,25(OH)D, and VDBP were measured in 91 MS patients and 92 HCs. Bioavailable and free concentrations were calculated. No difference in FGF23 (p = 0.65) and 25(OH)D/24.25(OH)2D ratio (p = 0.21) between MS patients and HCs was observed. Bioavailable 25(OH)D and bioavailable 1.25(OH)2D were lower (p < 0.01), while VDBP concentrations were higher in MS patients (p = 0.02) compared with HCs, specifically in male MS patients (p = 0.01). In conclusion, FGF23 and 25(OH)D/24.25(OH)2D did not differ between MS patients and HCs, yet bioavailable VitD concentrations are of potential clinical relevance in MS patients. The possible immunomodulating role of VDBP and gender-related differences in the VD-FGF23 axis in MS need further study.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D004872 Ergocalciferols Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24. Calciferols,Vitamin D 2,Ergocalciferol,Vitamin D2,D2, Vitamin
D005260 Female Females
D005346 Fibroblast Growth Factors A family of small polypeptide growth factors that share several common features including a strong affinity for HEPARIN, and a central barrel-shaped core region of 140 amino acids that is highly homologous between family members. Although originally studied as proteins that stimulate the growth of fibroblasts this distinction is no longer a requirement for membership in the fibroblast growth factor family. DNA Synthesis Factor,Fibroblast Growth Factor,Fibroblast Growth Regulatory Factor,Growth Factor, Fibroblast,Growth Factors, Fibroblast
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000089703 Fibroblast Growth Factor-23 A specific fibrobroblast growth factor that is primarily synthesized by OSTEOCYTES and OSTEOBLASTS. It is involved in regulating phosphate homeostasis and renal phosphate excretion. Fibroblast Growth Factor 23
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

Mariska C Vlot, and Laura Boekel, and Jolijn Kragt, and Joep Killestein, and Barbara M van Amerongen, and Robert de Jonge, and Martin den Heijer, and Annemieke C Heijboer
September 2023, Environmental science and pollution research international,
Mariska C Vlot, and Laura Boekel, and Jolijn Kragt, and Joep Killestein, and Barbara M van Amerongen, and Robert de Jonge, and Martin den Heijer, and Annemieke C Heijboer
January 1988, Pediatric nephrology (Berlin, Germany),
Mariska C Vlot, and Laura Boekel, and Jolijn Kragt, and Joep Killestein, and Barbara M van Amerongen, and Robert de Jonge, and Martin den Heijer, and Annemieke C Heijboer
November 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,
Mariska C Vlot, and Laura Boekel, and Jolijn Kragt, and Joep Killestein, and Barbara M van Amerongen, and Robert de Jonge, and Martin den Heijer, and Annemieke C Heijboer
October 1990, The American journal of clinical nutrition,
Mariska C Vlot, and Laura Boekel, and Jolijn Kragt, and Joep Killestein, and Barbara M van Amerongen, and Robert de Jonge, and Martin den Heijer, and Annemieke C Heijboer
October 2012, Cytokine,
Mariska C Vlot, and Laura Boekel, and Jolijn Kragt, and Joep Killestein, and Barbara M van Amerongen, and Robert de Jonge, and Martin den Heijer, and Annemieke C Heijboer
December 2021, eNeurologicalSci,
Mariska C Vlot, and Laura Boekel, and Jolijn Kragt, and Joep Killestein, and Barbara M van Amerongen, and Robert de Jonge, and Martin den Heijer, and Annemieke C Heijboer
July 2019, The Prostate,
Mariska C Vlot, and Laura Boekel, and Jolijn Kragt, and Joep Killestein, and Barbara M van Amerongen, and Robert de Jonge, and Martin den Heijer, and Annemieke C Heijboer
November 2012, Kidney international,
Mariska C Vlot, and Laura Boekel, and Jolijn Kragt, and Joep Killestein, and Barbara M van Amerongen, and Robert de Jonge, and Martin den Heijer, and Annemieke C Heijboer
March 2021, BMC nephrology,
Mariska C Vlot, and Laura Boekel, and Jolijn Kragt, and Joep Killestein, and Barbara M van Amerongen, and Robert de Jonge, and Martin den Heijer, and Annemieke C Heijboer
August 2012, International urology and nephrology,
Copied contents to your clipboard!